Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YK012 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT06565689Phase 1Recruiting
- Sponsor
- Excyte Biopharma Ltd
- Start
- May 2023
- Primary completion
- Dec 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YK012 in B-cell non-Hodgkin lymphoma (B-NHL), sponsored by Excyte Biopharma Ltd. Primary endpoints: Incidence of subjects with adverse events and/or serious adverse events, Dose-limiting toxicity and 1 more. Started May 2023; status: recruiting.
02
Drugs
YK012
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on NCT06565689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06565689.